Search
for

    Glossary Cromakalim

    potassium channel opener that relaxes blood vessels

    Cromakalim is a drug that acts as a potassium channel opener, which means it helps relax and widen blood vessels by allowing potassium ions to flow out of cells. This mechanism can improve blood flow and has been studied for its potential to treat conditions like hypertension and hair loss (alopecia) by enhancing circulation to hair follicles.

    Sort by

    Research 23

    1. The action of diazoxide and minoxidil sulphate on rat blood vessels: a comparison with cromakalim British Journal of Pharmacology · 1990 · 86 citations
    2. Comparison of the effects of the K+-channel openers cromakalim and minoxidil sulphate on vascular smooth muscle British Journal of Pharmacology · 1991 · 33 citations
    3. Inhibitory effects of the ATP-sensitive potassium channel openers cromakalim, pinacidil and minoxidil on the carbachol–response curve in porcine detrusor muscle Arab Journal of Urology · 2012 · 3 citations
    4. Glibenclamide reverses cromakalim-induced anti-ischemic effect in conscious rabbits Pharmacological Research · 1992 · 1 citations
    5. Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: From potassium channel openers to calcium entry blockers? European journal of medicinal chemistry · 2014 · 6 citations
    6. Potassium channel openers: pharmacological and clinical aspects Fundamental & Clinical Pharmacology · 1992 · 119 citations
    7. Potassium Channel Openers Stimulate DNA Synthesis in Mouse Epidermal Keratinocyte and Whole Hair Follicle Cultures Skin Pharmacology and Physiology · 1993 · 31 citations
    8. KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema Journal of Pharmacology and Experimental Therapeutics · 2020 · 18 citations
    9. Minoxidil Stimulates Elastin Expression in Aortic Smooth Muscle Cells Archives of Biochemistry and Biophysics · 1994 · 33 citations
    10. K <sub>ATP</sub> Channels and Cardiovascular Disease Circulation Research · 2013 · 144 citations
    11. Characterization of minoxidil/hydroxypropyl-β-cyclodextrin inclusion complex in aqueous alginate gel useful for alopecia management: Efficacy evaluation in male rat European Journal of Pharmaceutics and Biopharmaceutics · 2017 · 19 citations
    12. Chapter 20. Pathogenesis and Treatment of Alopecias Annual Reports in Medicinal Chemistry · 1989 · 8 citations
    13. The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia Pharmacology Research & Perspectives · 2020 · 6 citations
    14. Alopecia - the search for novel agents continues Expert Opinion on Therapeutic Patents · 1997 · 11 citations
    15. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations Frontiers in Pharmacology · 2026
    16. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. PubMed · 1988 · 48 citations
    17. Immunohistochemical, pharmacovigilance, and omics analyses reveal the involvement of ATP-sensitive K+ channel subunits in cancers: role in drug–disease interactions Frontiers in Pharmacology · 2023 · 3 citations
    18. Cantú Syndrome Is Caused by Mutations in ABCC9 The American Journal of Human Genetics · 2012 · 148 citations
    19. K channel therapeutics at the bedside Journal of Molecular and Cellular Cardiology · 2005 · 119 citations
    20. Efficacy of 5% Minoxidil versus Combined 5% Minoxidil and 0.01% Tretinoin for Male Pattern Hair Loss American Journal of Clinical Dermatology · 2007 · 43 citations
    21. Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K<sub>ATP</sub>Channel Mutations in Intact Cells 2023 · 1 citations
    22. Dose-Dependent Increases in Carotid Intima-Media Thickness Associated with Oral Minoxidil but Not Dutasteride in Healthy Young Males: A Randomized Controlled Pharmacological Trial Preprints.org · 2026
    23. Culprits of Medication-Induced Telogen Effluvium, Part 2 Cutis · 2024